RNA Target for Neurodegeneration (G106481539)

Target Name: RNU6-1139P

NCBI ID: G106481539

RNU6-1139P

Other Name(s): RNA, U6 small nuclear 1139, pseudogene

RNA Target for Neurodegeneration

RNA, U6 small nuclear 1139, pseudogene (R Nu6-1139P) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is a 24.8 kilobase (kb) RNA molecule that is expressed in the brain and other tissues.

The RNA molecule is composed of 1139 nontranscribing regions (NTRs) and is located on the 6th chromosome, specifically at position 1139 on the reference transcript. It is a pseudogene, which means that it is a non-coding RNA molecule that has the potential to encode a protein.

R Nu6-1139P has been shown to play a role in various cellular processes, including cell growth, differentiation, and neurotransmission. It has also been linked to various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the most promising aspects of R Nu6-1139P is its potential as a drug target. By targeting this molecule, researchers and pharmaceutical companies may be able to develop new treatments for a variety of neurological disorders.

In addition to its potential as a drug target, R Nu6-1139P also has the potential as a biomarker. By analyzing the expression levels of this molecule in brain tissue, researchers may be able to identify early signs of neurodegeneration and diagnose neuropsychiatric disorders at an early stage.

Overall, R Nu6-1139P is a promising molecule for research and potential drug development. As more research is conducted on this molecule, it is likely to emerge as a key player in the field of neuroscience and may help to lead to new treatments for a variety of neurological disorders.

Protein Name: RNA, U6 Small Nuclear 1139, Pseudogene

The "RNU6-1139P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNU6-1139P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets